Status:
COMPLETED
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
Lead Sponsor:
University of Rostock
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Allergic Asthma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
BDNF has been linked to the pathogenesis of airway hyperresponsiveness in asthma. In this trial, the impact of a treatment with salmeterol and salmeterol / fluticasone on BDNF concentrations will be a...
Eligibility Criteria
Inclusion
- Age \> 18 years, a physician's diagnosis of allergic asthma
- A documented sensitization to aero-allergens (pollen, animal hair, or house dust mite)
- A pre-bronchodilator forced expiratory volume in the first second (FEV1) \> 80 % of the predicted value (% predicted), a provocative concentration of histamine causing a 20 % fall in FEV1 (PC20) of \< 8 mg histamine / ml
Exclusion
- No regular treatment (only short-acting inhalers on demand were allowed)
- No history of or evidence for any other chronic disease than asthma
- No history of smoking, absence of any signs or symptoms of an infection
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00736801
Start Date
September 1 2005
End Date
April 1 2007
Last Update
August 21 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rostock
Rostock, Germany, 18057